Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine

2010 ◽  
Vol 82 (3) ◽  
pp. 476-484 ◽  
Author(s):  
Akira Ainai ◽  
Takeshi Ichinohe ◽  
Shin-ichi Tamura ◽  
Takeshi Kurata ◽  
Tetsutaro Sata ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Poly I:C ◽  
Adjuvant Activity ◽  
Mucosal Adjuvant

scholarly journals Correction to: A formulated poly (I:C)/CCL21 as an effective mucosal adjuvant for gamma‑irradiated influenza vaccine

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Ailar Sabbaghi ◽  
Masoud Malek ◽  
Sara Abdolahi ◽  
Seyed Mohammad Miri ◽  
Leila Alizadeh ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Poly I:C ◽  
Mucosal Adjuvant ◽  
Gamma Irradiated

scholarly journals Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity

PLoS ONE ◽  
2015 ◽  
Vol 10 (9) ◽  
pp. e0137608 ◽  
Author(s):  
Eun-Do Kim ◽  
Soo Jung Han ◽  
Young-Ho Byun ◽  
Sang Chul Yoon ◽  
Kyoung Sub Choi ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Mucosal Immunity ◽  
Poly I:C

scholarly journals Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b

Pharmaceutics ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 1237
Author(s):  
Signe Tandrup Schmidt ◽  
Dennis Christensen ◽  
Yvonne Perrie
Keyword(s):  
Large Scale ◽  
Colloidal Stability ◽  
Scale Up ◽  
Cationic Liposome ◽  
Poly I:C ◽  
Particle Sizes ◽  
Adjuvant Activity ◽  
Lipid Film ◽  
Gmp Production

Subunit vaccines require particulate adjuvants to induce the desired immune responses. Pre-clinical manufacturing methods of adjuvants are often batch dependent, which complicates scale-up for large-scale good manufacturing practice (GMP) production. The cationic liposomal adjuvant CAF09b, composed of dioctadecyldimethylammonium bromide (DDA), monomycoloyl glycerol analogue 1 (MMG) and polyinosinic:polycytidylic acid [poly(I:C)], is currently being clinically evaluated in therapeutic cancer vaccines. Microfluidics is a promising new method for large-scale manufacturing of particle-based medicals, which is scalable from laboratory to GMP production, and a protocol for production of CAF09b by this method was therefore validated. The influence of the manufacture parameters [Ethanol] (20–40% v/v), [Lipid] (DDA and MMG, 6–12 mg/mL) and dimethyl sulfoxide [DMSO] (0–10% v/v) on the resulting particle size, colloidal stability and adsorption of poly(I:C) was evaluated in a design-of-experiments study. [Ethanol] and [DMSO] affected the resulting particle sizes, while [Lipid] and [DMSO] affected the colloidal stability. In all samples, poly(I:C) was encapsulated within the liposomes. At [Ethanol] 30% v/v, most formulations were stable at 21 days of manufacture with particle sizes <100 nm. An in vivo comparison in mice of the immunogenicity to the cervical cancer peptide antigen HPV-16 E7 adjuvanted with CAF09b prepared by lipid film rehydration or microfluidics showed no difference between the formulations, indicating adjuvant activity is intact. Thus, it is possible to prepare suitable formulations of CAF09b by microfluidics.

scholarly journals Essential Role of Host Double-Stranded DNA Released from Dying Cells by Cationic Liposomes for Mucosal Adjuvanticity

Vaccines ◽  
2019 ◽  
Vol 8 (1) ◽  
pp. 8
Author(s):  
Rui Tada ◽  
Akihiro Ohshima ◽  
Yuya Tanazawa ◽  
Akari Ohmi ◽  
Saeko Takahashi ◽  
...  
Keyword(s):  
Essential Role ◽  
Cationic Liposome ◽  
Cationic Liposomes ◽  
Mucosal Vaccine ◽  
Nasal Administration ◽  
Adjuvant Activity ◽  
Mucosal Adjuvant ◽  
Double Stranded Dna ◽  
Dying Cells

Infectious disease remains a substantial cause of death. To overcome this issue, mucosal vaccine systems are considered to be a promising strategy. Yet, none are approved for clinical use, except for live-attenuated mucosal vaccines, mainly owing to the lack of effective and safe systems to induce antigen-specific immune responses in the mucosal compartment. We have reported that intranasal vaccination of an antigenic protein, with cationic liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane and 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl], induced antigen-specific mucosal and systemic antibody responses in mice. However, precise molecular mechanism(s) underlying the mucosal adjuvant effects of cationic liposomes remain to be uncovered. Here, we show that a host double-stranded DNA (dsDNA), released at the site of cationic liposome injection, plays an essential role for the mucosal adjuvanticity of the cationic liposome. Namely, we found that nasal administration of the cationic liposomes induced localized cell death, at the site of injection, resulting in extracellular leakage of host dsDNA. Additionally, in vivo DNase I treatment markedly impaired OVA-specific mucosal and systemic antibody production exerted by cationic liposomes. Our report reveals that host dsDNA, released from local dying cells, acts as a damage-associated molecular pattern that mediates the mucosal adjuvant activity of cationic liposomes.

scholarly journals Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome‐Formulated Influenza Vaccine ContainingEscherichia coliHeat‐Labile Toxin as a Mucosal Adjuvant

2000 ◽  
Vol 181 (3) ◽  
pp. 1129-1132 ◽  
Author(s):  
Reinhard Glück ◽  
Robert Mischler ◽  
Peter Durrer ◽  
Emil Fürer ◽  
Alois B. Lang ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Mucosal Adjuvant

scholarly journals The GM-CSF Released by Airway Epithelial Cells Orchestrates the Mucosal Adjuvant Activity of Flagellin

2020 ◽  
Vol 205 (10) ◽  
pp. 2873-2882
Author(s):  
Aneesh Vijayan ◽  
Laurye Van Maele ◽  
Delphine Fougeron ◽  
Delphine Cayet ◽  
Jean-Claude Sirard
Keyword(s):  
Epithelial Cells ◽  
Airway Epithelial Cells ◽  
Airway Epithelial ◽  
Adjuvant Activity ◽  
Mucosal Adjuvant ◽  
Gm Csf

scholarly journals Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization

2002 ◽  
Vol 76 (2) ◽  
pp. 517-524 ◽  
Author(s):  
Curtis P. Bradney ◽  
Gregory D. Sempowski ◽  
Hua-Xin Liao ◽  
Barton F. Haynes ◽  
Herman F. Staats
Keyword(s):  
Human Immunodeficiency Virus ◽  
Proinflammatory Cytokines ◽  
Adjuvant Activity ◽  
Mucosal Adjuvant ◽  
Mucosal Surfaces ◽  
Peptide Immunogen ◽  
Immunodeficiency Virus ◽  
Antibody Induction ◽  
Nasal Immunization ◽  
Anti Hiv

ABSTRACT Safe and potent new adjuvants are needed for vaccines that are administered to mucosal surfaces. This study was performed to determine if interleukin-1α (IL-1α) combined with other proinflammatory cytokines provided mucosal adjuvant activity for induction of systemic and mucosal anti-human immunodeficiency virus (HIV) peptide antibody when intranasally administered with an HIV peptide immunogen. Nasal immunization of BALB/c mice with 10 μg of an HIV env peptide immunogen with IL-1α, IL-12, and IL-18 on days 0, 7, 14, and 28 induced peak serum anti-HIV peptide immunoglobulin G1 (IgG1) and IgA titers of 1:131,072 and 1:7,131, respectively (P = 0.05 versus no adjuvant). The use of cholera toxin (CT) as a mucosal adjuvant induced serum IgG1 and IgA titers of 1:32,768 and 1:776, respectively. The adjuvant combination of IL-1α, IL-12, and IL-18 induced anti-HIV peptide IgA titers of 1:1,176, 1:7,131, and 1:4,705 in saliva, fecal extracts and vaginal lavage, respectively. Titers induced by the use of CT as an adjuvant were 1:223, 1:1,176, and 1:675, respectively. These results indicate that the proinflammatory cytokines IL-1α, IL-12, and IL-18 can replace CT as a mucosal adjuvant for antibody induction and are important candidates for use as mucosal adjuvants with HIV and other vaccines.

Sign in / Sign up

Export Citation Format

Share Document